Wikipedia

Moses Kamya

Moses R Kamya, is a Ugandan physician, academic, researcher and academic administrator, who serves as Professor and Chair of the Department Medicine, Makerere University School of Medicine, a component of Makerere University College of Health Sciences.[1][2]

Moses R Kamya
Born1960 (age 63–64)
Uganda
NationalityUgandan
CitizenshipUganda
Alma materMakerere University
(Bachelor of Medicine and Bachelor of Surgery)
(MMed in Internal Medicine)
University of California, Berkeley
(Master of Public Health)
University of Antwerp
(PhD in Biomedical Sciences)
Occupation(s)Physician and Academic
Years active1988 — present
TitleProfessor and Chair, Department Medicine, Makerere University
Spouse(Mrs Kamya)

Background and education

edit

Kamya was admitted to Makerere University School of Medicine in 1980, graduating in 1985, with a Bachelor of Medicine and Bachelor of Surgery. In 1988, he returned to the institution to study for the Master of Medicine (MMed) program. He graduated in 1991 with an MMed in Internal Medicine. He also holds a Master of Public Health in Epidemiology, awarded in 1995, by the University of California, Berkeley School of Public Health. His PhD in Biomedical Sciences was awarded by the University of Antwerp in 2007.[1]

Career

edit

Professor Kamya's research and teaching in infectious diseases spans a period in excess of 20 years. He specifically has special interest in the interaction between malaria and HIV/AIDS. He serves as Professor and Chair (Head) of the Department of Medicine at Makerere University College of Health Sciences. He is also a key researcher and case manager in AIDS care at Mulago National Referral Hospital, the teaching hospital of the university, and at the adjacent Makerere University Infectious Diseases Institute.[1][2]

His research spans HIV, malaria, tuberculosis, STDs. He trains medical students and residents in the design and execution of infectious diseases research. Among his many responsibilities, he also serves as editor of the Uganda antiretroviral therapy (ART) clinical guidelines. He is also the chair of the Uganda Ministry of Health adult ART management committee. He has published widely in peer journals and has contributed to several books on the subject matter,[1][2]

Researcher

edit

As an academic as well as a medical researcher, he has participated in research studies which has been published in respectable academic and scientific journals. Some of these among others include; Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. This study found significant cryptococcal meningitis associated mortality persists, despite the administration of amphotericin B and HIV therapy.[3] Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/μL who start HIV therapy in resource-limited settings.[4] HIV testing and treatment with the use of a community health approach in rural Africa.[5] Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy.[6] Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.[7] Dihydroartemisinin–piperaquine for the prevention of Malaria in pregnancy.[8] Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. This study concluded that light traps provide an alternative method for sampling indoor-resting mosquitoes to human-landing catches and have the advantage that they protect individuals from being bitten during collection, are easy to use and are not subject to collector bias.[9] Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda.[10] Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities.[11] Factors determining the heterogeneity of Malaria incidence in children in Kampala, Uganda.[12] Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for treatment of malaria: A randomized trial.[13] COVID-19: Shining the Light on Africa.[14] Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study.[15] and Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control.[16]

See also

edit

References

edit
  1. ^ a b c d "Professor Moses Kamya, MBChB, MMed, MPH, PhD: Professor and Chair, Department Medicine, Makerere University". Kampala: Makerere University-UCSF Research Collaboration. 21 October 2017. Retrieved 21 October 2017.
  2. ^ a b c IDI (15 March 2017). "Infectious Diseases Institute: Moses R. Kamya". Kampala: Makerere University Infectious Diseases Institute (IDI). Archived from the original on 21 October 2017. Retrieved 21 October 2017.
  3. ^ Kambugu, Andrew (2008). "Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy". Clinical Infectious Diseases. 46 (11): 1694–1701. doi:10.1086/587667. PMC 2593910. PMID 18433339.
  4. ^ Meya, David B. (2010). "Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings". Clinical Infectious Diseases. 51 (4): 448–455. doi:10.1086/655143. PMC 2946373. PMID 20597693.
  5. ^ Havlir, Diane V.; Balzer, Laura B.; Charlebois, Edwin D.; Clark, Tamara D.; Kwarisiima, Dalsone; Ayieko, James; Kabami, Jane; Sang, Norton; Liegler, Teri; Chamie, Gabriel; Camlin, Carol S.; Jain, Vivek; Kadede, Kevin; Atukunda, Mucunguzi; Ruel, Theodore (2019-07-18). "HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa". New England Journal of Medicine. 381 (3): 219–229. doi:10.1056/NEJMoa1809866. ISSN 0028-4793. PMC 6748325. PMID 31314966.
  6. ^ Kamya, Moses R; Mayanja-Kizza, Harriet; Kambugu, Andrew; Bakeera-Kitaka, Sabrina; Semitala, Fred; Mwebaze-Songa, Patricia; Castelnuovo, Barbara; Schaefer, Petra; Spacek, Lisa A; Gasasira, Anne F; Katabira, Elly; Colebunders, Robert; Quinn, Thomas C; Ronald, Allan; Thomas, David L (2007-10-01). "Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy". Journal of Acquired Immune Deficiency Syndromes. 46 (2): 187–193. doi:10.1097/QAI.0b013e31814278c0. ISSN 1525-4135. PMID 17693883. S2CID 41634539.
  7. ^ Yeka, Adoke; Gasasira, Anne; Mpimbaza, Arthur; Achan, Jane; Nankabirwa, Joaniter; Nsobya, Sam; Staedke, Sarah G.; Donnelly, Martin J.; Wabwire-Mangen, Fred; Talisuna, Ambrose; Dorsey, Grant; Kamya, Moses R.; Rosenthal, Philip J. (2012-03-01). "Malaria in Uganda: Challenges to control on the long road to elimination: I. Epidemiology and current control efforts". Acta Tropica. Tackling The Malaria "End Game": Regional Needs And Challenges For Successful Malaria Elimination. 121 (3): 184–195. doi:10.1016/j.actatropica.2011.03.004. ISSN 0001-706X. PMC 3156969. PMID 21420377.
  8. ^ Kakuru, Abel; Jagannathan, Prasanna; Muhindo, Mary K.; Natureeba, Paul; Awori, Patricia; Nakalembe, Miriam; Opira, Bishop; Olwoch, Peter; Ategeka, John; Nayebare, Patience; Clark, Tamara D.; Feeney, Margaret E.; Charlebois, Edwin D.; Rizzuto, Gabrielle; Muehlenbachs, Atis (2016-03-10). "Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy". New England Journal of Medicine. 374 (10): 928–939. doi:10.1056/NEJMoa1509150. ISSN 0028-4793. PMC 4847718. PMID 26962728.
  9. ^ Kilama, Maxwell; Smith, David L.; Hutchinson, Robert; Kigozi, Ruth; Yeka, Adoke; Lavoy, Geoff; Kamya, Moses R.; Staedke, Sarah G.; Donnelly, Martin J.; Drakeley, Chris; Greenhouse, Bryan; Dorsey, Grant; Lindsay, Steve W. (2014-03-21). "Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda". Malaria Journal. 13 (1): 111. doi:10.1186/1475-2875-13-111. ISSN 1475-2875. PMC 4001112. PMID 24656206.
  10. ^ Asua, Victor (2020). "Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda". The Journal of Infectious Diseases. pp. 985–994. doi:10.1093/infdis/jiaa687. PMC 8006419. PMID 33146722. Retrieved 2023-02-03.
  11. ^ Helb, Danica A.; Tetteh, Kevin K. A.; Felgner, Philip L.; Skinner, Jeff; Hubbard, Alan; Arinaitwe, Emmanuel; Mayanja-Kizza, Harriet; Ssewanyana, Isaac; Kamya, Moses R.; Beeson, James G.; Tappero, Jordan; Smith, David L.; Crompton, Peter D.; Rosenthal, Philip J.; Dorsey, Grant (2015-08-11). "Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities". Proceedings of the National Academy of Sciences. 112 (32): E4438-47. Bibcode:2015PNAS..112E4438H. doi:10.1073/pnas.1501705112. ISSN 0027-8424. PMC 4538641. PMID 26216993.
  12. ^ Tamara, D. Clark (2008). "Factors Determining the Heterogeneity of Malaria Incidence in Children in Kampala, Uganda". The Journal of Infectious Diseases. 198 (3): 393–400. doi:10.1086/589778. PMID 18522503. S2CID 13085319.
  13. ^ Kamya, Moses R.; Yeka, Adoke; Bukirwa, Hasifa; Lugemwa, Myers; Rwakimari, John B.; Staedke, Sarah G.; Talisuna, Ambrose O.; Greenhouse, Bryan; Nosten, François; Rosenthal, Philip J.; Wabwire-Mangen, Fred; Dorsey, Grant (2007-05-18). "Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial". PLOS Clinical Trials. 2 (5): e20. doi:10.1371/journal.pctr.0020020. ISSN 1555-5887. PMC 1876597. PMID 17525792.
  14. ^ Rosenthal, Philip J.; Breman, Joel G.; Djimde, Abdoulaye A.; John, Chandy C.; Kamya, Moses R.; Leke, Rose G. F.; Moeti, Matshidiso R.; Nkengasong, John; Bausch, Daniel G. (2020-06-03). "COVID-19: Shining the Light on Africa". The American Journal of Tropical Medicine and Hygiene. 102 (6): 1145–1148. doi:10.4269/ajtmh.20-0380. ISSN 0002-9637. PMC 7253089. PMID 32372749.
  15. ^ Andolina, Chiara; Rek, John C; Briggs, Jessica; Okoth, Joseph; Musiime, Alex; Ramjith, Jordache; Teyssier, Noam; Conrad, Melissa; Nankabirwa, Joaniter I; Lanke, Kjerstin; Rodriguez-Barraquer, Isabel; Meerstein-Kessel, Lisette; Arinaitwe, Emmanuel; Olwoch, Peter; Rosenthal, Philip J (2021-11-01). "Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study". The Lancet Infectious Diseases. 21 (11): 1568–1578. doi:10.1016/S1473-3099(21)00072-4. ISSN 1473-3099. PMC 8554388. PMID 34146476.
  16. ^ Kilama, Maxwell; Lindsay, Steve W.; Greenhouse, Bryan; Arinaitwe, Emmanuel; Kamya, Moses R.; Staedke, Sarah G.; Katureebe, Agaba; Wanzira, Humphrey; Rosenthal, Philip J.; Kigozi, Simon P.; Drakeley, Chris; Smith, David L.; Tatem, Andrew J.; Barusya, Chris; Dorsey, Grant (2015-05-06). "Malaria Transmission, Infection, and Disease at Three Sites with Varied Transmission Intensity in Uganda: Implications for Malaria Control". The American Journal of Tropical Medicine and Hygiene. 92 (5): 903–912. doi:10.4269/ajtmh.14-0312. ISSN 0002-9637. PMC 4426576. PMID 25778501.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Moses_Kamya&oldid=1174892446"